Switzerland· 56072002

Erbitux

A cetuximab product containing cetuximabum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01FE01

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedErbituxATCL01FE01REGISTER NO.56072002PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Cetuximab is registered in 12 of 19 countries.

Countries holding a registration under ATC L01FE01 (cetuximab), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Cetuximab · ATC L01FE01

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
cetuximabum
Manufacturer
—
Country
Switzerland (CH)
ATC code
L01FE01
ATC class
Cetuximab
Defined daily dose
65 mg, P
Swissmedic category
A
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680560720025
    Durchstf 100 ml
    CHF 1035.65

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

18 interactions on record for cetuximab.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Cetuximab · interactions on record

18 records

  • 2 severe
  • 16 moderate

Most severe, free to view

  • Aminolevulinic acidL01XD04severe
  • ThalidomideL04AX02severe
  • OmeprazoleA02BC01moderate
  • PantoprazoleA02BC02moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Cetuximab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cetuximab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Erbitux
  • Liechtenstein · Erbitux
  • Norway · Erbitux

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9a76ac87-df01-4f75-8f9c-34cdf07f133c
GET /v1/drugs/9a76ac87-df01-4f75-8f9c-34cdf07f133c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "cetuximabum 500 mg",
  "valid_from": "2015-11-01",
  "limitations": "[{\"description\":\"Die Behandlung bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes:<br>\\n<br>\\nVergütung bei Patienten mit metastasiertem Kolorektalkarzinom mit nicht-mutiertem Wildtyp-Ras-Gen:<br>\\n- In Kombination mit FOLFIRI oder FOLFOX<br>\\n- Als Monotherapie, wenn eine Therapie auf Oxaliplatin- und Irinotecan-Basis versagt hat oder eine Irinotecan-Intoleranz vorliegt.<br>\\n<br>\\nVergütung bei Patienten mit lokal fortgeschrittenem Plattenepithelkarzinom im Kopf-Hals-Bereich (ausgenommen nasopharyngeale Karzinome), die eine Behandlung mit Cisplatin nicht vertragen:<br>\\n- In Kombination mit Radiotherapie.<br>\\n<br>\\nVergütung bei Patienten mit rezidivierendem und/oder metastasiertem Plattenepithelkarzinom im Kopf-Hals-Bereich (ausgenommen nasopharyngeale Karzinome):<br>\\n- In Kombination mit bis zu 6 Zyklen Cisplatin und 5-Fluorouracil. Anschliessend wird die Erhaltungstherapie mit Erbitux alleine bis zur Tumorprogression weiter vergütet.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2024-03-01\",\"validTo\":null}]",
  "galenic_form": "Inf Lös 500 mg/100ml",
  "therapeutic_area": null,
  "sl_inclusion_date": "2015-11-01",
  "self_retention_pct": 10
}

See everything about cetuximab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.